In conclusion, our study findings add insights into metabolic disorders associated with obesity, with a focus on alterations in the gut–liver–adipose tissue system, in which the LPS/LBP axis may be implicated with unexpected roles, thus opening new scenarios for risk stratification strategies and therapeutic approaches. This evidence concerns the gene LBP and metabolic disease.